Insider Trading & Ownership of Lynx1 Capital Management LP

Location
Dorado
Summary
The estimated value of insider holdings of Lynx1 Capital Management LP is at least $123,082,942 dollars as of 23 Dec 2025. Lynx1 Capital Management LP is the 10%+ Owner of Cullinan Therapeutics, Inc. and owns shares of Cullinan Therapeutics, Inc. (CGEM) stock worth about $75.3M. Lynx1 Capital Management LP is the 10%+ Owner of TScan Therapeutics, Inc. and owns shares of TScan Therapeutics, Inc. (TCRX) stock worth about $37.21M. Lynx1 Capital Management LP is the 10%+ Owner of Neuphoria Therapeutics Inc. and owns shares of Neuphoria Therapeutics Inc. (NEUP) stock worth about $10.38M. Lynx1 Capital Management LP is the 10%+ Owner of Passage BIO, Inc. and owns shares of Passage BIO, Inc. (PASG) stock worth about $195.3K.
Signature
Lynx1 Capital Management LP, By: Lynx1 Capital Management GP LLC, its general partner, By: /s/ Weston Nichols, Sole Member
All Insider Reports
All Insider Reports

Notify me when Lynx1 Capital Management LP files a new Insider Trading report.

⭐ Subscribe ⭐

Ownership of Lynx1 Capital Management LP

Symbol Company Relationship Holdings Value Past Year Net Change Change % Report Period
CGEM Cullinan Therapeutics, Inc. 10%+ Owner $75,297,881 +$13,322,539 +21% 28 Oct 2025
TCRX TScan Therapeutics, Inc. 10%+ Owner $37,208,412 +$3,252,079 +9.6% 19 Dec 2025
NEUP Neuphoria Therapeutics Inc. 10%+ Owner $10,381,390 21 Oct 2025
PASG Passage BIO, Inc. 10%+ Owner $195,259 11 Sep 2025

Insider Transactions Reported by Lynx1 Capital Management LP:

Sym Company Class Transaction % Value $ * Price $ Shares Shares After Date Ownership
* An asterisk sign (*) next to the price indicates that the price is likely invalid.